Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout
Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the news was broadcasted. The deal is expected to close by the end of the first quarter.
Viela Bio proved its worth in the pharmaceutical industry after winning the approval for its Uplizna, a drug that received FDA approval for Neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition. It is the only approved drug available in ...
